- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01604369
Cryoablation as Standard Treatment of Atrial Flutter (CASTAF)
Cryoablation as Standard Treatment of Atrial Flutter - Long Term Efficacy and Patient Content
The hypothesis of the present study is to evaluate cryoablation(cooling of the tissue) as standard therapy of common atrial flutter,focusing on efficacy, feasibility, procedure time, and patient content.
The purpose of this study is to determine whether cryoablation, performed only by operators experienced in cryothermic ablation is effective and safe in the treatment of atrial flutter.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atrial flutter (AFL), a common atrial tachyarrhythmia may cause significant symptoms and serious adverse effects including embolic stroke, myocardial ischemia and congestive heart failure. Currently, radiofrequency (RF) catheter ablation of the cavotricuspid isthmus (CTI) is considered first-line therapy for treatment of CTI-dependent AFL. However, RF ablation of the CTI is associated with significant pain during lesion delivery. Furthermore, RF ablation can potentially injure cardiac structures adjacent to the CTI such as the AV node, tricuspid valve and right coronary artery. RF ablation can also lead to steam pops, cardiac tamponade and fatal complications have also been reported in association with CTI-ablation. Ablation using cryothermal energy (Cryo) has several potential advantages over RF ablation including greater catheter stability due to adherence to myocardial tissue during applications, reduced risk of thrombus formation, systemic embolization, and lower risk of myocardial perforation due to preservation of tissue architecture.
The investigators have in a prospective randomized, single centre study (CRAFT) investigated efficacy and safety of RF versus Cryo for atrial flutter, and showed that cryoablation is as effective as RF ablation in the short and long term. The patients perceived significantly less pain and required significantly lower doses of analgesia and sedation during cryoablation compared to RF ablation. The study was powered for non-inferiority with 75 patients in each group.
The objective of the present study is to expand the findings from the CRAFT study in a larger cohort of patients, letting only operators experienced in cryothermic CTI ablation use Cryo as standard therapy focusing on efficacy, feasibility, procedure time, and patient content.
To perform an ablation within the study, the electrophysiologist must have a previous experience of a minimum of 25 cryoablations of atrial flutter.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, SE-14186
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consecutive patients referred to our institution for ablation therapy of ECG-documented, typical CTI dependent AFL.
- Patients above the age of 18 having symptomatic CTI-dependent AFL documented on a 12-lead ECG with typical ECG appearance of negative saw tooth waves in the inferior limb leads and positive deflections in V1 or positive saw tooth waves in the inferior limb leads and negative deflections in V1.
- Patients with a history of atrial fibrillation will only be included if they have predominant atrial flutter under chronic treatment with class I or III antiarrhythmic agents.
Exclusion Criteria:
- prior ablation for AFL;
- atrial flutter related to recently undergone surgery, hyperthyroidism or other severe disease;
- inability to adhere with the study protocol;
- pregnancy;
- predominant atrial fibrillation; and
- for patients with persistent atrial flutter contraindication to warfarin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cryoablation
|
Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava.
Ablation is performed at a target temperature of -80 ºC.
Each application will last for 240 seconds.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy
Time Frame: One year after intervention
|
Clinical success defined as the freedom from atrial flutter evaluated at the 12-month follow-up.
|
One year after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: During and up to one year after intervention
|
The secondary endpoints will be acute ablation success defined as bidirectional CTI-block, safety assessed by the rate of periprocedural complications, procedure and fluoroscopy times and the level of pain experienced by the patient during the ablation procedure.
|
During and up to one year after intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mats Jensen-Urstad, Professor, Karolinska University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KS1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Flutter
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
University of PennsylvaniaWithdrawnTypical Atrial Flutter | Risk Factors With Future Development of Atrial FlutterUnited States
-
Angelo BivianoCompleted
-
Kaiser PermanenteActive, not recruitingAtrial Fibrillation and FlutterUnited States
-
Charles University, Czech RepublicCompleted
-
Hospital Universitario Central de AsturiasJohnson & JohnsonUnknown
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of ManchesterManchester University NHS Foundation TrustWithdrawn
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
-
Abbott Medical DevicesCompletedTypical Atrial FlutterUnited States, Canada
Clinical Trials on Medtronic Freezor Max Cardiac Cryoablation Catheter
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedParoxysmal Atrial Fibrillation (PAF)United States, Canada
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedTachycardia, Atrioventricular Nodal ReentryUnited States
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Disease | Supraventricular Tachycardia | AtrioVentricular Nodal Reentrant TachycardiaUnited States, Canada
-
Uppsala University HospitalMedtronic; Swedish Heart Lung FoundationUnknownAtrial FibrillationSweden
-
Boston Scientific CorporationCompleted
-
Medtronic Cardiac Rhythm and Heart FailureRecruiting
-
Medtronic Cardiac Rhythm and Heart FailureRecruitingPersistent Atrial FibrillationUnited States, Austria, Germany, Italy, United Kingdom, Poland